*Together with Option Pit & Stock Market Media
Good day, 360!
Special Guest TODAY (Kenny Glick): Tune in at 2pm EST to hear from an old friend 😄 about how to trade the VWAP. It can help you make money in any kind of market, but you have to know HOW to use it.
FOCUS LIST🔎
LIPO – Up over 30% in pre after announcing U.S. patent allowance for Innovative Liposomal Drug Delivery Platform
WOLF – Up over 23% in pre after announcing $750M in Proposed Funding from U.S. CHIPS Act and Additional $750M From Investment Group Led By Apollo
HOTH – Up over 18% in pre after announcing award of key U.S patent for groundbreaking Alzheimer’s treatment and prepares for clinical trials of HT-ALZ with formulation now underway
*Together with Stock Market Media
“Volume-weighted average price” – VWAP – is a force. And it can help you make a lot of money in any kind of market.
But you have to know how to use it.
That’s where “The Warlock” Kenny Glick comes in.
HOTLIST🔥
LIPO – Up over 30% in pre after announcing U.S. patent allowance for Innovative Liposomal Drug Delivery Platform
Lipella Pharmaceuticals Inc. (LIPO) is a biotechnology company that focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications.
In the pre-market this morning, the company announcedthe receipt of a notice of allowance from the U.S. Patent and Trademark Office (USPTO) for its proprietary liposomal drug delivery platform.
The patent application, U.S. Patent No. 17/829,960, titled “Delivery of Agents Using Metastable Liposomes,” covers key innovations in Lipella’s platform technology for delivering therapeutic agents via liposome-based vehicles.
The stock traded up over 30% in the pre-market in reaction to the news.
The $0.52 area acted as resistance and now becomes a potential support area.
Above it, targets to the upside are $0.56, $0.62 and then the pre-market high at $0.65. Beyond that, targets to the upside are $0.78, $0.89, $0.9687 and then $1.10.
Below $0.52, targets to the downside are $0.50, $0.48, $0.45 and then a gap fill at $0.4087.
WOLF – Up over 23% in pre after announcing $750M in Proposed Funding from U.S. CHIPS Act and Additional $750M From Investment Group Led By Apollo
Wolfspeed Inc. (WOLF) operates as a bandgap semiconductor company that focuses on silicon carbide and gallium nitride (GaN) technologies in Europe, Hong Kong, China, rest of Asia-Pacific, the United States, and internationally.
In the pre-market this morning, the company announced that it had signed a non-binding preliminary memorandum of terms (PMT) with the U.S. Department of Commerce for up to $750 million in proposed direct funding under the CHIPS and Science Act.
In addition, a consortium of investment funds led by Apollo, The Baupost Group, Fidelity Management & Research Company and Capital Group have agreed to provide Wolfspeed an additional $750 million of new financing.
Together these investments support Wolfspeed’s long-term growth plans and bolster domestic production of silicon carbide to power clean energy systems underpinning electric vehicles (EVs), artificial intelligence (AI) data centers, battery storage and more.
The stock traded up over 23% in the pre-market in reaction to the news.
The first target for bulls is the pre-market high at $15.53. Beyond that $19 and $21 come into play.
Below $14.49, targets to the downside are $13.60, $13, $12.50, $12 and then a gap fill at $11.38.
*Together with Option Pit
In the closing 30 minutes, there’s 20% more volume than the open, which can mean substantial movement to pull profits more easily than any other time of the day.
Use this to your advantage with volume-trading pro, Voz!
WED, OCT 16th @ 2PM EST
HOTH – Up over 18% in pre after announcing award of key U.S patent for groundbreaking Alzheimer’s treatment and prepares for clinical trials of HT-ALZ with formulation now underway
Hoth Therapeutics Inc. (HOTH) is a clinical-stage biopharmaceutical company that focuses on developing therapies for unmet medical needs.
In the pre-market this morning, the company announcedthe granting of a U.S. patent for its pioneering Alzheimer’s treatment, HT-ALZ. This milestone patent secures the company’s intellectual property rights to its novel therapeutic approach, as Hoth accelerates preparations for clinical trials.
HT-ALZ represents a breakthrough in Alzheimer’s treatment, specifically targeting the Substance P/Neurokinin-1 Receptor pathway.
The stock traded up over 18% in the pre-market in reaction to the news.
The first target for bulls is the pre-market high at $1.12. Beyond that, $1.25, $1.50, $1.70 and $2 come into play.
Below $1.12, targets to the downside are $1, $0.94, $0.90 and then a gap fill at $0.82.
MARKET NEWS 📰
P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas!
Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull
DISCLAIMER: To more fully understand any Ragingbull.com, LLC (“RagingBull”) subscription, website, application or other service (“Services”), please review our full disclaimer located at https://ragingbull.com/disclaimer
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision.
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers’ trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.
RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers.
RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled.
*Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals.
WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.
